Back to Global NewsPublished: 23 Feb 2026Download AppJoin TelegramWhy Foghorn's New CFO Could Turbocharge Biotech Returns – What Investors Must Know#Foghorn Therapeutics#Ryan Maynard#Biotech CFO#Healthcare Investing#Biopharma Executive Moves#Sector TrendsDownload AppJoin CommunityShare Article